Michael Burkes Brophy sold $89k of NTRA
CHIEF FINANCIAL OFFICER at Natera, Inc.. 610 shares at an average of $145.55, traded Apr 21, 2025, filed Apr 22, 2025.
Score components
- +22RoleCFO
- +9Trade size$89k at market
- 0Share of holdings soldSold 0.8% of holdings
- +15Cluster8 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-011195, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 20, 2025 | MOption exercise Common Stock10b5-1 | +1,521 | - | - | 77,078 | Apr 22, 2025 |
| Apr 21, 2025 | SOpen-market sale Common Stock10b5-1 | -602 | $145.54 | $88k | 76,476 | Apr 22, 2025 |
| Apr 21, 2025 | SOpen-market sale Common Stock10b5-1 | -8 | $146.16 | $1,169 | 76,468 | Apr 22, 2025 |
| Apr 20, 2025 | MOption exercise Restricted Stock Unitderivative10b5-1 | -1,521 | $0.00 | $0 | 4,566 | Apr 22, 2025 |
Related signals
Other insiders at Natera, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 38Weak | Natera, Inc. | Steven Leonard Chapman CEO AND PRESIDENT | $526k 1,273 shares | -1% | |
| 40Moderate | Natera, Inc. | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | $1.2M 3,000 shares | -3% | |
| 55Moderate | Natera, Inc. | Jonathan Sheena director, other | $7.0M 18,064 shares | -100% | |
| 35Weak | Natera, Inc. | Jonathan Sheena director, other | $3.2M 9,150 shares | -4% | |
| 40Moderate | Natera, Inc. | Matthew Rabinowitz EXECUTIVE CHAIRMAN | $35M 102,000 shares | -5% | |
| 40Moderate | Natera, Inc. | Matthew Rabinowitz EXECUTIVE CHAIRMAN | $16M 50,000 shares | -2% | |
| 39Weak | Natera, Inc. | Steven Leonard Chapman CEO AND PRESIDENT | $545k 1,698 shares | -2% | |
| 45Moderate | Natera, Inc. | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | $5.9M 18,160 shares | -14% | |
| 50Moderate | Natera, Inc. | Rowan E Chapman director | $1.1M 4,366 shares | -43% | |
| 45Moderate | Natera, Inc. | Steven Leonard Chapman CEO AND PRESIDENT | $1.0M 4,400 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.